Understanding how certain bacteria can kill harmful pathogens
Identifying the genetic basis of strain specific antimicrobial activity against a major foodborne pathogen
This study is looking at how certain bacteria can make natural substances that fight off germs that cause foodborne illnesses, and it’s for anyone interested in understanding how we can better protect our health from harmful bacteria.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10993161 on NIH RePORTER |
What this research studies
This research investigates the genetic factors that enable specific strains of bacteria to produce antimicrobial substances that can target and kill harmful pathogens, particularly those that cause foodborne illnesses. By studying the interactions between these bacteria and their environment, the researchers aim to identify the molecules responsible for this antimicrobial activity. The project will involve laboratory experiments to characterize these substances and their effectiveness against various bacterial strains, including those that affect human health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of foodborne illnesses or have conditions related to bacterial infections.
Not a fit: Patients with viral infections or those not affected by foodborne pathogens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for bacterial infections, particularly those related to foodborne pathogens.
How similar studies have performed: Previous research has shown promise in using bacteriocins and similar antimicrobial agents to combat bacterial infections, indicating a potential for success in this approach.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Baltrus, David a — University of Arizona
- Study coordinator: Baltrus, David a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.